World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
118
Citations
77528
World Ranking
3975
National Ranking
2173

Overview

Richard M. Goldberg is affiliated with West Virginia University in the United States. Their research primarily focuses on medicine, with significant contributions in oncology and related subfields such as pathology and forensic medicine, pulmonary and respiratory medicine, cancer research, and surgery.

The scientist's work extensively covers several topics within oncology, including colorectal cancer treatments and studies, genetic factors in colorectal cancer, gastric cancer management and outcomes, cancer genomics and diagnostics, colorectal cancer screening and detection, pancreatic and hepatic oncology research, and colorectal and anal carcinomas.

Frequent coauthors in their research include:

  • Heinz-Josef Lenz
  • Francesca Battaglin
  • Joanne Xiu
  • Anthony F. Shields
  • Qian Shi

Richard M. Goldberg has published numerous papers in notable venues, with a focus on the treatment and molecular characteristics of colorectal cancer. Significant publication venues include the Journal of Clinical Oncology, UNC Libraries, Annals of Oncology, European Journal of Cancer, and the International Journal of Cancer.

Key recent publications by this scientist are:

  • "Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials," 2020, Journal of Clinical Oncology
  • "Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors," 2020, International Journal of Cancer
  • "A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer," 2023, Journal of Clinical Oncology
  • "Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer," 2021, JAMA
  • "Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)," 2020, Clinical Cancer Research

Best Publications

  • PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

    Dung T. Le;Jennifer N. Uram;Hao Wang;Bjarne R. Bartlett

  • Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

    Dung T. Le;Dung T. Le;Jennifer N. Durham;Jennifer N. Durham;Kellie N. Smith;Hao Wang

  • Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    Axel Grothey;Eric Van Cutsem;Alberto Sobrero;Salvatore Siena

  • A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer

    Richard M. Goldberg;Daniel J. Sargent;Roscoe F. Morton;Charles S. Fuchs

  • Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer

    Christine M. Ribic;Daniel J. Sargent;Malcolm J. Moore;Malcolm J. Moore;Stephen N. Thibodeau

  • Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781

    Joel Tepper;Mark J. Krasna;Donna Niedzwiecki;Donna Hollis

  • Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment

    Axel Grothey;Daniel Sargent;Richard M. Goldberg;Hans Joachim Schmoll

  • Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

    Sharlene Gill;Charles L. Loprinzi;Daniel J. Sargent;Stephan D. Thomé

  • A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.

    Daniel J. Sargent;Richard M. Goldberg;Stacy D. Jacobson;John S. Macdonald

  • Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

    Hedy Lee Kindler;Donna Niedzwiecki;Donna Hollis;Susan Sutherland

  • Immunohistochemistry Versus Microsatellite Instability Testing in Phenotyping Colorectal Tumors

    Noralane M. Lindor;Lawrence J. Burgart;Olga Leontovich;Richard M. Goldberg

  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

    Alan P. Venook;Donna Niedzwiecki;Heinz Josef Lenz;Federico Innocenti

  • Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel J. Sargent;Harry S. Wieand;Daniel G. Haller;Richard Gray

  • Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel Sargent;Alberto Sobrero;Axel Grothey;Michael J. O'Connell

  • Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

    Carmen J. Allegra;Greg Yothers;Michael J. O'Connell;Saima Sharif

  • Lower Cancer Incidence in Amsterdam-I Criteria Families Without Mismatch Repair Deficiency: Familial Colorectal Cancer Type X

    Noralane M. Lindor;Kari Rabe;Gloria M. Petersen;Robert Haile

  • Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study

    Steven R. Alberts;William L. Horvath;William C. Sternfeld;Richard M. Goldberg

  • Platinum neurotoxicity pharmacogenetics

    Sarah R. McWhinney;Richard M. Goldberg;Howard L. McLeod

  • Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841

    Jan Franko;Qian Shi;Charles D. Goldman;Barbara A. Pockaj

  • Cetuximab in the treatment of colorectal cancer.

    Richard M Goldberg;Alan P Venook;Richard L Schilsky

Frequent Co-Authors

Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California
Axel Grothey
Axel Grothey University of Tennessee at Knoxville
Donna Niedzwiecki
Donna Niedzwiecki Duke University
Alan P. Venook
Alan P. Venook University of California, San Francisco
Robert J. Mayer
Robert J. Mayer Dana-Farber Cancer Institute
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in the medical field but seeking alternatives to the traditional MD path, a variety of related online degrees and career options are available. Many students pursue administrative or advanced practice roles that are highly valued in today’s healthcare landscape.

If you’re drawn to the leadership side of healthcare, finding which online healthcare administration programs have CAHME accreditation? is a smart starting point. CAHME-accredited MHA programs ensure a rigorous curriculum recognized across the industry.

For current registered nurses looking to upgrade credentials with more flexibility, there are RN to BSN with no clinicals programs, making it possible to earn your degree entirely online and at your own pace.

Nurses interested in advancing further can also explore doctoral options. If speed is your priority, discover the quickest DNP program offerings online, expediting your path to leadership and teaching positions. Alternatively, those on a budget may want to learn more about the cheapest online DNP programs to balance affordability with career advancement.

These alternative pathways offer flexibility, affordability, and accessibility—opening doors to a wide range of roles in medicine and healthcare.

Best Scientists Citing Richard M. Goldberg

Trending Scientists